[go: up one dir, main page]

MX2024014571A - Moduladores basados en pirimidina y usos de los mismos - Google Patents

Moduladores basados en pirimidina y usos de los mismos

Info

Publication number
MX2024014571A
MX2024014571A MX2024014571A MX2024014571A MX2024014571A MX 2024014571 A MX2024014571 A MX 2024014571A MX 2024014571 A MX2024014571 A MX 2024014571A MX 2024014571 A MX2024014571 A MX 2024014571A MX 2024014571 A MX2024014571 A MX 2024014571A
Authority
MX
Mexico
Prior art keywords
based modulators
pyrimidine based
formula
compounds
pyrimidine
Prior art date
Application number
MX2024014571A
Other languages
English (en)
Inventor
Hong Lin
Juan Luengo
Neil Johnson
Audrey Hospital
Jin Zeng
Original Assignee
Quanta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanta Therapeutics Inc filed Critical Quanta Therapeutics Inc
Publication of MX2024014571A publication Critical patent/MX2024014571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se proporcionan en la presente compuestos, tal como compuestos de la Fórmula (I), Fórmula (I-A), Fórmula (I-b), o sales farmacéuticamente aceptables de cualquiera de estos, útiles para modular KRAS GD12 y/u otros mutantes GD12.
MX2024014571A 2022-05-25 2024-11-25 Moduladores basados en pirimidina y usos de los mismos MX2024014571A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263345794P 2022-05-25 2022-05-25
US202263380544P 2022-10-21 2022-10-21
US202363486934P 2023-02-24 2023-02-24
PCT/US2023/023445 WO2023230190A1 (en) 2022-05-25 2023-05-24 Pyrimidine based modulators and uses thereof

Publications (1)

Publication Number Publication Date
MX2024014571A true MX2024014571A (es) 2025-05-02

Family

ID=87060028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024014571A MX2024014571A (es) 2022-05-25 2024-11-25 Moduladores basados en pirimidina y usos de los mismos

Country Status (11)

Country Link
US (2) US12145947B2 (es)
EP (1) EP4532494A1 (es)
JP (1) JP7791361B2 (es)
KR (1) KR20250034204A (es)
CN (1) CN119604501A (es)
AU (1) AU2023276596A1 (es)
CA (1) CA3257281A1 (es)
IL (1) IL317601A (es)
MX (1) MX2024014571A (es)
WO (1) WO2023230190A1 (es)
ZA (1) ZA202410007B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4532494A1 (en) 2022-05-25 2025-04-09 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
AU2024212035A1 (en) 2023-01-26 2025-08-14 Arvinas Operations, Inc. Cereblon-based kras degrading protacs ans uses related thereto
EP4680609A1 (en) 2023-03-15 2026-01-21 Quanta Therapeutics, Inc. Kras modulators and uses thereof
KR20250164828A (ko) 2023-03-30 2025-11-25 레볼루션 메디슨즈, 인크. Ras gtp 가수분해 유도를 위한 조성물 및 이의 용도
TW202508595A (zh) 2023-05-04 2025-03-01 美商銳新醫藥公司 用於ｒａｓ相關疾病或病症之組合療法
WO2024259169A1 (en) * 2023-06-13 2024-12-19 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof
WO2025016899A1 (en) * 2023-07-19 2025-01-23 Bayer Aktiengesellschaft Spirocyclic compounds for the treatment of cancer
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
TW202515570A (zh) 2023-08-17 2025-04-16 美商樹線生物科學公司 螺環二氫哌喃并嘧啶ｋｒａｓ抑制劑
WO2025049619A1 (en) * 2023-08-29 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2025049641A1 (en) * 2023-08-29 2025-03-06 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2025064848A1 (en) 2023-09-21 2025-03-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyridine kras inhibitors
WO2025080946A2 (en) 2023-10-12 2025-04-17 Revolution Medicines, Inc. Ras inhibitors
WO2025106905A1 (en) * 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination therapies with a kras modulator and an immunomodulator inhibitor
WO2025106901A1 (en) * 2023-11-17 2025-05-22 Quanta Therapeutics, Inc. Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025245127A1 (en) 2024-05-21 2025-11-27 Treeline Biosciences, Inc. Spirocyclic dihydropyranopyrimidine kras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE372966T1 (de) 1994-03-25 2007-09-15 Isotechnika Inc Verbesserung der effektivität von arzneimitteln duren deuterierung
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
RU2006102955A (ru) 2003-07-02 2007-08-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Пиримидины, пригодные в качестве модуляторов потенциалзависимых ионных каналов
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
BRPI0718874A2 (pt) 2006-12-22 2015-06-23 Novartis Ag Compostos orgânicos
NZ600126A (en) 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
US20110166135A1 (en) 2008-09-10 2011-07-07 Hiroshi Morimoto Aromatic nitrogen-containing 6-membered ring compounds and their use
WO2010064705A1 (ja) 2008-12-05 2010-06-10 大日本住友製薬株式会社 Ｈ４受容体アンタゴニスト作用を有する新規７位置換ジヒドロピラノピリミジン誘導体
WO2010120996A1 (en) 2009-04-17 2010-10-21 Wyeth Llc 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
WO2014172639A1 (en) 2013-04-19 2014-10-23 Ruga Corporation Raf kinase inhibitors
JP6787892B2 (ja) 2014-11-20 2020-11-18 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｉｒａｋインヒビターとしてのヘテロアリール化合物及びその使用
MX2018005967A (es) 2015-11-16 2018-08-29 Araxes Pharma Llc Compuestos de quinazolina 2-sustituida que comprenden un grupo heterociclico sustituido y metodos de uso de los mismos.
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
JP7039489B2 (ja) 2016-05-18 2022-03-22 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
US11318137B2 (en) 2017-05-17 2022-05-03 Vanderbilt University Quinazoline compounds as modulators of Ras signaling
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有ｍｇａｔ２抑制活性的縮合環衍生物
US10647715B2 (en) 2017-11-15 2020-05-12 Mirati Therapeutics, Inc. KRas G12C inhibitors
US12134620B2 (en) * 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
JP7592601B2 (ja) 2019-01-10 2024-12-02 ミラティ セラピューティクス， インコーポレイテッド Ｋｒａｓ ｇ１２ｃ阻害剤
JP7068743B2 (ja) 2019-01-11 2022-05-17 塩野義製薬株式会社 Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
US20220227738A1 (en) 2019-05-20 2022-07-21 California Institute Of Technology Kras g12c inhibitors and uses thereof
WO2020239123A1 (zh) 2019-05-31 2020-12-03 上海翰森生物医药科技有限公司 芳香杂环类衍生物调节剂、其制备方法和应用
CN112409331B (zh) 2019-08-21 2024-02-20 上海翰森生物医药科技有限公司 杂环类衍生物抑制剂、其制备方法和应用
AU2020337938B2 (en) 2019-08-29 2025-09-25 Array Biopharma Inc. KRas G12D inhibitors
US20220402916A1 (en) 2019-09-18 2022-12-22 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
CN114630832A (zh) 2019-11-15 2022-06-14 四川海思科制药有限公司 一种嘧啶并环衍生物及其在医药上的应用
WO2021106231A1 (en) 2019-11-29 2021-06-03 Taiho Pharmaceutical Co., Ltd. A compound having inhibitory activity against kras g12d mutation
BR112022010267A2 (pt) 2019-12-27 2022-08-16 Wigen Biomedicine Tech Shanghai Co Ltd Composto, composição farmacêutica, e uso dos compostos
WO2021139748A1 (en) 2020-01-08 2021-07-15 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic tetrahydroquinazolines
US20230135152A1 (en) 2020-02-11 2023-05-04 AcuraStem Incorporated Pikfyve kinase inhibitors
KR20230019462A (ko) 2020-06-02 2023-02-08 베링거 인겔하임 인터내셔날 게엠베하 암 치료용 고리형 2-아미노-3-시아노 티오펜 및 유도체
US20230242544A1 (en) 2020-06-30 2023-08-03 InventisBio Co., Ltd. Quinazoline compounds, preparation methods and uses thereof
US20230339976A1 (en) 2020-08-04 2023-10-26 Mirati Therapeutics, Inc. Kras g12d inhibitors
WO2022040469A1 (en) 2020-08-19 2022-02-24 The Trustees Of The Stevens Institute Of Technology Spiro compounds as kras inhibitors
US20230357233A1 (en) 2020-08-26 2023-11-09 InventisBio Co., Ltd. Heteroaryl compounds, preparation methods and uses thereof
CN116368130A (zh) 2020-08-28 2023-06-30 金橘生物科技公司 杂环化合物及其用途
US20230081426A1 (en) 2020-09-18 2023-03-16 Plexxikon Inc. Compounds and methods for kras modulation and indications therefor
CN116964036A (zh) 2020-11-20 2023-10-27 北京加科思新药研发有限公司 Kras g12d抑制剂
TW202229285A (zh) 2020-11-20 2022-08-01 大陸商北京加科思新藥研發有限公司 Kras g12d抑制劑
EP4247369A4 (en) 2020-11-23 2024-10-16 Merck Sharp & Dohme LLC SPIROCYCLIC-SUBSTITUTED 6,7-DIHYDRO-PYRANO[2,3-D]PYRIMIDINE INHIBITORS OF THE KRAS G12C MUTANT
WO2022115439A1 (en) 2020-11-25 2022-06-02 California Institute Of Technology Kras g12c inhibitors and uses thereof
US12398154B2 (en) 2020-12-15 2025-08-26 Mirati Therapeutics, Inc. Azaquinazoline pan-KRas inhibitors
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2022127827A1 (zh) 2020-12-17 2022-06-23 上海维申医药有限公司 Kras g12c蛋白突变抑制剂、其制备方法、药物组合物及其应用
US20240109893A1 (en) 2020-12-22 2024-04-04 Shanghai Kechow Pharma, Inc. Preparation and application method of heterocyclic compounds as kras inhibitor
CN114685502A (zh) 2020-12-25 2022-07-01 由理生物医药（上海）有限公司 作为kras-g12c抑制剂的螺环类化合物
CN114685460A (zh) 2020-12-31 2022-07-01 贝达药业股份有限公司 Kras g12c抑制剂及其在医药上的应用
US20240140957A1 (en) 2021-01-08 2024-05-02 Beigene Switzerland Gmbh Bridged compounds as kras g12d inhibitor and degrader and the use thereof
WO2022156761A1 (en) 2021-01-21 2022-07-28 Ascentage Pharma (Suzhou) Co., Ltd. Spirocyclic indenes
WO2022170999A1 (zh) 2021-02-09 2022-08-18 南京明德新药研发有限公司 吡啶[4，3-d]嘧啶类化合物
CA3207854A1 (en) 2021-02-09 2022-08-18 Liansheng Li Heterocyclic compounds and uses thereof
MX2023008463A (es) 2021-02-16 2023-12-07 Leidos Biomedical Res Inc Composiciones y métodos para la inhibición del gen del virus de sarcoma de rata kirsten (kras).
WO2022184178A1 (en) 2021-03-05 2022-09-09 Jacobio Pharmaceuticals Co., Ltd. Kras g12d inhibitors
WO2022187527A1 (en) 2021-03-05 2022-09-09 Nikang Therapeutics, Inc Quinazoline nitrile derivatives as kras inhibitors
US20240166669A1 (en) 2021-03-05 2024-05-23 Nikang Therapeutics, Inc. Quinazoline amine derivatives as kras inhibitors
WO2022188729A1 (en) 2021-03-07 2022-09-15 Jacobio Pharmaceuticals Co., Ltd. Fused ring derivatives useful as kras g12d inhibitors
JP2024510207A (ja) 2021-03-12 2024-03-06 ブリストル－マイヤーズ スクイブ カンパニー Ｋｒａｓ阻害剤
ES3013592T3 (en) 2021-03-12 2025-04-14 Bristol Myers Squibb Co Kras g12d inhibitors
CN116964058A (zh) 2021-03-15 2023-10-27 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
TWI814234B (zh) 2021-03-15 2023-09-01 大陸商藥雅科技（上海）有限公司 突變蛋白抑制劑的製備及其應用
WO2022194191A1 (en) 2021-03-16 2022-09-22 Guangdong Newopp Biopharmaceuticals Co., Ltd. Heterocyclic compounds as inhibitors of kras g12d
WO2022194245A1 (zh) 2021-03-17 2022-09-22 劲方医药科技(上海)有限公司 嘧啶并环类化合物及其制法和用途
WO2022194192A1 (zh) 2021-03-18 2022-09-22 四川科伦博泰生物医药股份有限公司 一类杂芳环化合物、其制备方法及用途
US20250255868A1 (en) 2021-04-09 2025-08-14 Hangzhou Innogate Pharma Co., Ltd. Heterocyclic compound acting as kras g12d inhibitor
WO2022217118A1 (en) 2021-04-09 2022-10-13 Quanta Therapeutics, Inc. Pyrimidine based ras modulators and uses thereof
WO2022221386A1 (en) 2021-04-14 2022-10-20 Erasca, Inc. Selective kras inhibitors
WO2022221739A1 (en) 2021-04-16 2022-10-20 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12d mutant
WO2022232331A1 (en) 2021-04-29 2022-11-03 Amgen Inc. Heterocyclic compounds and methods of use
JP2024517693A (ja) 2021-04-29 2024-04-23 アムジエン・インコーポレーテツド ２－アミノベンゾチアゾール化合物及びその使用方法
CN117203207A (zh) 2021-04-30 2023-12-08 江苏恒瑞医药股份有限公司 桥环类化合物、其制备方法及其在医药上的应用
US20240300980A1 (en) 2021-05-22 2024-09-12 Shanghai Kechow Pharma, Inc. Heterocyclic compounds as kras inhibitor, and preparation therefor and use thereof in treatment
WO2022251576A1 (en) 2021-05-28 2022-12-01 Merck Sharp & Dohme Corp. Small molecule inhibitors of kras g12c mutant
WO2022256459A1 (en) 2021-06-01 2022-12-08 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2022261210A1 (en) 2021-06-08 2022-12-15 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266069A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Tricyclic kras g12d inhibitors
EP4361157A4 (en) 2021-06-21 2024-10-16 Jiangsu Hengrui Pharmaceuticals Co., Ltd. FUSED TETRACYCLIC COMPOUND, ITS PREPARATION METHOD AND ITS USE IN MEDICINE
WO2022271658A1 (en) 2021-06-23 2022-12-29 Erasca, Inc. Tricyclic kras inhibitors
WO2022271823A1 (en) 2021-06-23 2022-12-29 Newave Pharmaceutical Inc. Mutant kras modulators and uses thereof
TW202317100A (zh) 2021-06-23 2023-05-01 瑞士商諾華公司 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途
KR20240024928A (ko) 2021-06-23 2024-02-26 노파르티스 아게 Kras 돌연변이 단백질의 억제제로서의 피라졸릴 유도체
CA3223602A1 (en) 2021-06-24 2022-12-29 Robert Field SHOEMAKER Erk1/2 and kras g12c inhibitors combination therapy
WO2023274324A1 (zh) 2021-06-30 2023-01-05 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用
EP4363412A4 (en) 2021-06-30 2025-05-14 Dana-Farber Cancer Institute, Inc. Small-molecule inhibitors of the KRAS G12D mutant
AU2022303440A1 (en) 2021-07-02 2024-02-22 Shanghai De Novo Pharmatech Co., Ltd. Kras g12d inhibitor and use thereof
CN117460737A (zh) 2021-07-05 2024-01-26 四川科伦博泰生物医药股份有限公司 杂芳环化合物、其制备方法及用途
CN116249683B (zh) 2021-07-06 2024-07-26 浙江海正药业股份有限公司 氘甲基取代吡嗪并吡嗪并喹啉酮类衍生物、其制备方法及其在医药上的应用
CN117751116A (zh) 2021-07-07 2024-03-22 微境生物医药科技(上海)有限公司 作为KRas G12D抑制剂的稠环化合物
IL309642A (en) 2021-07-07 2024-02-01 Incyte Corp Tricyclic compounds as inhibitors of Kras
WO2023001123A1 (zh) 2021-07-19 2023-01-26 上海艾力斯医药科技股份有限公司 新型吡啶并嘧啶衍生物
JP2024525993A (ja) 2021-07-23 2024-07-12 スゾウ、ザンロン、ファーマ、リミテッド Ｋｒａｓ ｇ１２ｄ阻害剤およびその使用
WO2023061294A1 (zh) 2021-10-13 2023-04-20 再鼎医药(上海)有限公司 含氮杂环类衍生物调节剂、其制备方法及应用
CA3235146A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras
CN115974896A (zh) 2021-10-15 2023-04-18 广东东阳光药业有限公司 新的嘧啶并吡啶化合物、其药物组合物及其用途
CA3234429A1 (en) 2021-10-15 2023-04-20 Luc Farmer Ras inhibitors, compositions and methods of use thereof
US20240425501A1 (en) 2021-10-21 2024-12-26 Sanjita Sasmal Novel bicyclic heteroaryl derivatives as sos1:kras proteinprotein interaction inhibitors
WO2023066371A1 (zh) 2021-10-22 2023-04-27 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023072188A1 (zh) 2021-10-29 2023-05-04 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
WO2023072297A1 (zh) 2021-11-01 2023-05-04 江苏恒瑞医药股份有限公司 含氮的四环化合物、其制备方法及其在医药上的应用
WO2023077441A1 (en) 2021-11-05 2023-05-11 Ranok Therapeutics (Hangzhou) Co. Ltd. Methods and compositions for targeted protein degradation
JP2024540410A (ja) 2021-11-05 2024-10-31 フロンティア メディシンズ コーポレーション Ｋｒａｓ ｇ１２ｃ阻害剤
EP4430035A4 (en) 2021-11-09 2025-10-29 1200 Pharma Llc SELECTED KRAS G12C INHIBITORS AND THEIR USES
JP2024543879A (ja) 2021-11-24 2024-11-26 メルク・シャープ・アンド・ドーム・エルエルシー Ｋｒａｓ変異型タンパク質の小分子阻害剤
EP4405337A4 (en) 2021-11-30 2025-11-26 Beta Pharma Inc Fused pyrimidine derivatives as kras oncoprotein inhibitors
KR20240128852A (ko) 2021-12-01 2024-08-27 베링거 인겔하임 인터내셔날 게엠베하 암 치료를 위한 고리형 2-아미노-3-시아노 티오펜 및 유도체
JP2024543982A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング がんの処置のための縮環２－アミノ－３－シアノチオフェン及び誘導体
JP2024543975A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN118574835A (zh) 2021-12-01 2024-08-30 勃林格殷格翰国际有限公司 用于治疗癌症的环状2-氨基-3-氰基噻吩及衍生物
WO2023099620A1 (en) 2021-12-01 2023-06-08 Boehringer Ingelheim International Gmbh Kras degrading compounds comprising annulated 2-amino-3-cyano thiophenes
JP2024543976A (ja) 2021-12-01 2024-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 癌の処置のための環化２－アミノ－３－シアノチオフェン及び誘導体
CN117940436A (zh) 2021-12-02 2024-04-26 上海和誉生物医药科技有限公司 一种7-(萘-1-基)吡啶并[4,3-d]嘧啶衍生物及其制备和应用
CN116217591A (zh) 2021-12-02 2023-06-06 思路迪生物医药(上海)有限公司 一类作为kras g12d突变抑制剂的吡啶并嘧啶类衍生物
CN118055932A (zh) 2021-12-02 2024-05-17 上海和誉生物医药科技有限公司 一种kras抑制剂及其制备和在药学上的应用
WO2023103906A1 (zh) 2021-12-07 2023-06-15 贝达药业股份有限公司 Kras g12d抑制剂及其在医药上的应用
CN116253748A (zh) 2021-12-09 2023-06-13 苏州浦合医药科技有限公司 取代的双环杂芳基化合物作为kras g12d抑制剂
EP4444719A1 (en) 2021-12-10 2024-10-16 Vrise Therapeutics, Inc. 5,6,7,8-tetrahydro-2,6-naphthyridine derivatives as cancer therapeutics
WO2023114733A1 (en) 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
US20250163039A1 (en) 2021-12-22 2025-05-22 Boehringer Ingelheim International Gmbh Heteroaromatic compounds for the treatment of cancer
CN116332959A (zh) 2021-12-24 2023-06-27 苏州泽璟生物制药股份有限公司 Krasg12d蛋白水解调节剂及其制备方法和应用
WO2023119677A1 (en) 2021-12-24 2023-06-29 Astellas Pharma Inc. Pharmaceutical composition comprising a quinazoline compound
WO2023125627A1 (en) 2021-12-28 2023-07-06 Lynk Pharmaceuticals Co., Ltd. Nitrogen-containing heterocyclic compound and application thereof
WO2023130012A1 (en) 2021-12-29 2023-07-06 Development Center For Biotechnology Compounds for mutant kras protein degradation and uses thereof
WO2023125989A1 (zh) 2021-12-31 2023-07-06 上海医药集团股份有限公司 一种喹唑啉类化合物及其应用
TW202337466A (zh) 2022-01-06 2023-10-01 美商德洛斯股份有限公司 用於抑制ｒａｓ之組合物及方法
US20250084079A1 (en) 2022-01-06 2025-03-13 Theras, Inc. Compositions and methods for inhibition of ras
CN118434747A (zh) 2022-01-11 2024-08-02 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法、中间体及应用
WO2023137223A1 (en) 2022-01-17 2023-07-20 Newave Pharmaceutical Inc. Pan-kras inhibitors and uses thereof
CN116514844A (zh) 2022-01-20 2023-08-01 思路迪生物医药(上海)有限公司 一类噻吩并嘧啶类衍生物及其作为泛kras突变抑制剂的用途
US20250206732A1 (en) 2022-01-21 2025-06-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of kras
WO2023138524A1 (zh) 2022-01-24 2023-07-27 贝达药业股份有限公司 Kras g12d降解剂及其在医药上的应用
CN118679170A (zh) 2022-01-28 2024-09-20 上海艾力斯医药科技股份有限公司 一种含氮杂环化合物、其制备方法及应用
AU2023216698A1 (en) 2022-02-03 2024-06-13 Mirati Therapeutics, Inc. Quinazoline pan-kras inhibitors
IL314812A (en) 2022-02-09 2024-10-01 Quanta Therapeutics Inc Kras modulators and uses thereof
WO2023152255A1 (en) 2022-02-10 2023-08-17 Bayer Aktiengesellschaft Fused pyrimidines as kras inhibitors
WO2023151621A1 (zh) 2022-02-11 2023-08-17 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
EP4532494A1 (en) 2022-05-25 2025-04-09 Quanta Therapeutics, Inc. Pyrimidine based modulators and uses thereof

Also Published As

Publication number Publication date
US20250243222A1 (en) 2025-07-31
WO2023230190A1 (en) 2023-11-30
AU2023276596A1 (en) 2025-01-02
IL317601A (en) 2025-02-01
EP4532494A1 (en) 2025-04-09
CA3257281A1 (en) 2023-11-30
JP2025522309A (ja) 2025-07-15
KR20250034204A (ko) 2025-03-10
US20240199650A1 (en) 2024-06-20
JP7791361B2 (ja) 2025-12-23
US12145947B2 (en) 2024-11-19
ZA202410007B (en) 2025-09-25
CN119604501A (zh) 2025-03-11

Similar Documents

Publication Publication Date Title
ZA202410007B (en) Pyrimidine based modulators and uses thereof
ZA202406129B (en) Kras modulators and uses thereof
MX2025010707A (es) Moduladores de kras y usos de los mismos
ZA202207667B (en) Sulfonimidamide compounds as nlrp3 modulators
ZA202110422B (en) Heterocyclic compounds, preparation methods and uses thereof
WO2021127404A8 (en) Tricyclic pyridones and pyrimidones
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2022007842A (es) Derivados biciclicos sustituidos de piperidina utiles como activadores de celulas t.
WO2021079196A3 (en) Mettl3 modulators
MX2024013838A (es) Compuestos y usos de estos
CR20230413A (es) Moduladores de sting (estimulador de genes de interferón)
MX2023009045A (es) Derivados novedosos de pirimidin-2-il sulfonamida.
MX2022014126A (es) Moduladores de enpp1 y usos de los mismos.
MX2025004959A (es) Derivados de triazinona como inhibidores de inflamasoma de proteina 3 que contiene dominios de pirina (nlrp3)
MX2024003475A (es) Polimorfos como inhibidores de erbb.
MX2025005972A (es) Compuestos novedosos como moduladores de la inhibicion de la proteina 3 que contiene un dominio de pirina de la familia de receptores similares al dominio de oligomerizacion de union a nucleotidos (nlrp3)
MX2025003568A (es) Compuestos y composiciones útiles como inhibidores de las proteínas inhibidoras de la apoptosis (iap)
ZA202500857B (en) Compounds and methods for modulating her2
MX2023009954A (es) Compuestos de aminopirimidina y métodos de uso de estos.
WO2023147063A3 (en) Compounds and methods for yap/tead modulation and indications therefor
WO2022031862A3 (en) Heteroaryl and heterocyclyl compounds
WO2024086744A3 (en) Compositions and uses thereof
PH12023553004A1 (en) Modulators of trex1
WO2023150591A3 (en) Pyridazinone compounds as trpa1 inhibitors
MX2023014817A (es) Inhibidores de ripk1 de nicotinamida.